AntriaBio

Financials

Investors

Financials

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Jun. 30, 2016
Current assets    
Cash $ 4,486,538 $ 4,062,013
Other current assets 442,015 430,094
Total current assets 4,928,553 4,492,107
Non-current assets    
Fixed assets, net 5,325,401 5,984,670
Intangible assets, net 44,322 51,614
Deferred lease asset 86,293 0
Deposits 244,341 375,000
Total non-current assets 5,700,357 6,411,284
Total Assets 10,628,910 10,903,391
Current liabilities:    
Accounts payable and accrued expenses 1,652,677 1,500,650
Convertible notes payable 10,000 60,000
Deferred lease liability, current portion 105,295 119,688
Lease payable, current portion 0 23,128
Interest payable 2,762 15,079
Warrant derivative liability 588 11,955
Total current liabilities 1,771,322 1,730,500
Non-current liabilities:    
Deferred lease liability, less current portion 304,575 400,038
Deposit liability 25,046 0
Total non-current liabilities 329,621 400,038
Total Liabilities 2,100,943 2,130,538
Commitments and Contingencies (Note 13)
Stockholders' equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 49,228,640 and 35,110,916 shares issued and outstanding, June 30, 2017 and 2016, respectively 49,230 35,114
Additional paid-in capital 72,800,699 52,782,569
Accumulated deficit (64,321,962) (44,044,830)
Total stockholders' equity 8,527,967 8,772,853
Total Liabilities and Stockholders' Equity $ 10,628,910 $ 10,903,391
v3.7.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Research and development    
Compensation and benefits $ 7,001,151 $ 4,374,763
Consultants and outside costs 762,670 1,317,465
Material manufacturing costs 2,596,809 2,414,708
Facilities and other costs 1,734,104 1,341,452
Research and development 12,094,734 9,448,388
General and administrative    
Compensation and benefits 5,569,426 3,891,916
Professional fees 1,100,480 441,978
Investor relations 327,556 259,351
General and administrative 1,231,852 909,657
General and Administrative 8,229,314 5,502,902
Total operating expenses 20,324,048 14,951,290
Loss from operations (20,324,048) (14,951,290)
Other income (expense)    
Interest income 0 965
Interest expense (1,595) (5,039)
Rental income 37,144 0
Derivative income 11,367 19,822
Total other income 46,916 15,748
Net loss (20,277,132) (14,935,542)
Warrant modification deemed dividend (3,406,932) 0
Cummulative preferred stock dividend 0 (5,974,385)
Net Loss attributable to common stock $ (23,684,064) $ (20,909,927)
Net loss per common share - basic and diluted $ (0.57) $ (0.84)
Weighted average number of common shares outstanding - basic and diluted 41,296,741 24,773,213
v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net Loss $ (20,277,132) $ (14,935,542)
Amortization of intangible asset 7,292 7,292
Depreciation expense 1,106,878 743,962
Stock-based compensation expense 6,005,670 3,761,837
Warrant expense 12,564 72,972
Derivative gains (11,367) (19,822)
Changes in operating assets and liabilities:    
Increase in other assets (68,762) (42,083)
Increase in deferred lease asset (86,293) 0
Increase in accounts payable and accrued expenses 112,347 26,370
(Decrease) increase in interest payable (2,800) 2,000
Decrease in deferred lease liability (109,856) (105,484)
Net Cash Used In Operating Activities (13,311,459) (10,488,498)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (407,929) (2,091,790)
Receipt of sublease deposit 25,046 0
Return of security deposit 187,500 187,500
Decrease in restricted cash 0 450,167
Net Cash Used In Investing Activities (195,383) (1,454,123)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on capital lease payable (23,128) (93,851)
Proceeds from issuance of equity financing 14,637,689 5,362,521
Proceeds from issuance of preferred stock 0 6,347,615
Payment of placement agent compensation and issuance costs (683,194) (890,357)
Net Cash Provided By Financing Activities 13,931,367 10,725,928
Net increase (decrease) in cash 424,525 (1,216,693)
Cash - Beginning of Year 4,062,013 5,278,706
Cash - End of Year 4,486,538 4,062,013
Cash Paid During the Period for:    
Taxes 0 0
Interest 0 0
Non-Cash Transactions:    
Warrant value recorded as issuance costs 753,079 750,484
Conversion of note payable into common stock 50,000 0
Conversion of interest payable to common stock 9,517 0
Fair value of warrant modifications recorded as a deemed dividend 3,406,932 0
Conversion of preferred stock to common stock 0 5,923,200
Deemed dividend on conversion of preferred stock 0 5,811,708
Series A Preferred Stock dividend paid in stock 0 162,677
Tenant Improvements    
Non-Cash Transactions:    
Fixed assets acquired 0 46,049
Accounts payable and Accrued expenses [Member]    
Non-Cash Transactions:    
Fixed assets acquired $ 39,680 $ 65,881